Elicio Therapeutics (ELTX) Change in Account Payables (2020 - 2026)
Elicio Therapeutics (ELTX) reported Change in Account Payables of -$460000.0 for Q1 2026, down 115.34% on a YoY basis from $3.0 million in Q1 2025, and down 231.05% quarter-over-quarter from $351000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Change in Account Payables (2020 - 2026) Analysis & Trends
Elicio Therapeutics has reported Change in Account Payables for 7 years, with the latest figure at -$460000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 115.34% year-over-year to -$460000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.8 million (down 230.46% YoY), and the FY2025 full-year result was -$366000.0, up 89.01% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$460000.0, down from $351000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.1 million in Q2 2022, with the low at -$3.5 million in Q3 2025.
- Historically, Change in Account Payables has averaged -$177000.0 across 5 years, with a median of -$172000.0 in 2025.
- The largest YoY upside for Change in Account Payables was 554.23% in 2024 against a maximum downside of 2265.0% in 2024.
- Elicio Therapeutics' Change in Account Payables stood at -$282000.0 in 2022, then soared by 85.82% to -$40000.0 in 2023, then plunged by 2265.0% to -$946000.0 in 2024, then surged by 137.1% to $351000.0 in 2025, then sank by 231.05% to -$460000.0 in 2026.
- The last three Change in Account Payables figures came in at -$460000.0 (Q1 2026), $351000.0 (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | -460,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -460,000.00 |
| Mar 31, 2026 | -460,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | -3.54 Mn |
| Sep 30, 2025 | -3.54 Mn |
| Jun 30, 2025 | -172,000.00 |
| Jun 30, 2025 | -172,000.00 |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | -946,000.00 |
| Dec 31, 2024 | -946,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Mar 31, 2024 | -3.26 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -40,000.00 |
| Dec 31, 2023 | -40,000.00 |